NeurologyLive® Friday 5 — May 16, 2025

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: New Treatments, Global Collaboration Highlight 2025 Peripheral Nerve Society Annual Meeting

Committee chairs Vincent Timmerman, PhD, MSc, and Kathrin Doppler, MD, provide a preview of the 2025 PNS Annual Meeting, giving clinicians an inside look at what to expect from the upcoming conference.

2: A Mother’s Journey Through Diagnosis and Acceptance of Duchenne Muscular Dystrophy: Debra Miller

The chief executive officer and founder at CureDuchenne shared her emotional journey from her son’s diagnosis of Duchenne to embracing a new path focused on advocacy, adaptation, and resilience. [WATCH TIME: 4 minutes]

3: Insights on Quanterix Simoa Assay to Diagnose Alzheimer Disease: Mark Roskey, PhD

The chief scientific officer at Quanterix gave a clinical overview on how the company’s Simoa platform enables ultrasensitive detection of neurodegeneration biomarkers in blood, transforming Alzheimer and Parkinson disease research. [WATCH TIME: 3 minutes]

4: NeuroVoices: Ajay Gupta, MD, on Phenotyping Tuberous Sclerosis Complex Into Disease Clusters

The director of the Tuberous Sclerosis Program at Cleveland Clinic provided clinical commentary on a novel clustering analysis in TSC, revealing how phenotype-genotype insights can lead to more personalized treatment and surveillance.

5: Advancing ALS Through Gene Therapies, Early Intervention, and Multidisciplinary Care: Brian Lin, PhD

The research portfolio director at the Muscular Dystrophy Association discussed the evolving ALS therapeutic landscape, highlighting advances in genetic and RNA-based interventions. [WATCH TIME: 6 minutes]